The World Anti-doping Authority (WADA) has said its appeal against the acquittal of 34 past and present Australian Football League (AFL) players will be heard on November 16.
The appeal was lodged against the players, who were a part of the 2012 Essendon Bombers squad, after they were initially acquitted of any wrongdoing by the AFL Anti-Doping Tribunal in March, reports Xinhua.
It has been known for months the Court of Arbitration for Sport (CAS) would hear appeal in Sydney later this year, but the date, November 16, was finalised on Wednesday.
On Tuesday, CAS estimated the appeal would run for five to seven days. A verdict, typically, would follow weeks later.
In March this year, the tribunal was not "comfortably satisfied" the Australian Sports Anti-doping Authority (ASADA) had proved Essendon players had categorically used thymosin beta-4 (TB4), a banned performance enhancing drug, as part of their supplements program in 2012.
ASADA chief executive Ben McDevitt did not opt to appeal the original decision, instead saying he would "support" WADA if they decided to initiate their own appeal.
WADA uncovered new findings relating to TB4 from samples taken from players during the supplement regime in 2012, but Essendon remains confident the evidence will not be enough to overturn the result.
"It is clear that WADA does not know what the results mean," Essendon chief executive Xavier Campbell told the Australian Broadcast Corporation earlier this month following the release.
"There were no supporting documents or evidence in the WADA brief and there are real doubts as to the significance of these claims."
Last week, Essendon coach James Hird, who has taken considerable flak for overseeing the controversial supplements period, stepped down from the role following a string of poor on-field results.
After the new information came to light, Hird said he was "comfortable" it would not damage the players' case as it meant "nothing".
Earlier this month, News Limited released all 1294 pages of transcript from ASADAs investigation of, what it described as, Australian football's "greatest crisis", which revealed players had painful side-effects from the injections.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
